The French company Valneva, with which the European Commission had announced that it was on the verge of concluding a contract for the advance purchase of Covid-19 vaccines (see EUROPE B12635A3), indicated, on Tuesday 20 April, that it was “deprioritising” these negotiations.
It will now focus “on bilateral discussions” - with EU and non-EU countries - to supply its candidate vaccine (VLA2001), which recently showed positive results in its Phase 1/2 clinical trial.
“We’ve...